Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVEONASDAQ:CBIONASDAQ:ONCYNASDAQ:ORMPNASDAQ:SESN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVEOAVEO Pharmaceuticals$15.00$14.97$3.06▼$15.00$521.45M1601,442 shs247,800 shsCBIOCrescent Biopharma$15.89+2.2%$0.00$11.06▼$63.00$310.65M1.5248,291 shs171,070 shsONCYOncolytics Biotech$0.90+14.4%$0.55$0.33▼$1.53$84.95M1.07675,184 shs1.54 million shsORMPOramed Pharmaceuticals$2.18+1.1%$2.20$1.82▼$3.09$89.22M1.59141,723 shs18,026 shsSESNSesen Bio$10.50$0.37▼$12.58$2.56B0.831.07 million shs93,330 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVEOAVEO Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CBIOCrescent Biopharma0.00%-0.06%-97.93%-97.93%-97.93%ONCYOncolytics Biotech0.00%+20.04%+150.28%+70.77%-12.52%ORMPOramed Pharmaceuticals0.00%+1.58%-1.62%+4.00%-14.69%SESNSesen Bio0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVEOAVEO PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACBIOCrescent Biopharma3.3305 of 5 stars3.80.00.03.72.51.70.6ONCYOncolytics Biotech1.6767 of 5 stars3.43.00.00.02.00.00.0ORMPOramed Pharmaceuticals0.262 of 5 stars0.03.00.00.00.00.80.6SESNSesen BioN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVEOAVEO Pharmaceuticals 0.00N/AN/AN/ACBIOCrescent Biopharma 3.67Strong Buy$25.0057.33% UpsideONCYOncolytics Biotech 2.75Moderate Buy$4.33380.95% UpsideORMPOramed Pharmaceuticals 2.00HoldN/AN/ASESNSesen Bio 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ONCY, AVEO, ORMP, CBIO, and SESN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025CBIOCrescent BiopharmaStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$28.006/20/2025CBIOCrescent BiopharmaTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/18/2025CBIOCrescent BiopharmaLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$22.005/21/2025ONCYOncolytics BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.005/16/2025ONCYOncolytics BiotechJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVEOAVEO Pharmaceuticals$42.29M12.33N/AN/A$1.33 per share11.28CBIOCrescent Biopharma$10K31,064.95N/AN/A$8.24 per share1.93ONCYOncolytics BiotechN/AN/AN/AN/A$0.05 per shareN/AORMPOramed Pharmaceuticals$1.34M66.58N/AN/A$3.61 per share0.60SESNSesen Bio$40M0.00N/A3.39$0.78 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVEOAVEO Pharmaceuticals-$53.34M-$0.84N/A28.85N/A-30.79%-81.66%-28.83%N/ACBIOCrescent Biopharma-$37.88M-$46.00N/AN/AN/AN/A-293.92%-206.20%N/AONCYOncolytics Biotech-$23.14M-$0.29N/AN/AN/AN/A-313.77%-130.19%7/30/2025 (Estimated)ORMPOramed Pharmaceuticals-$19.06M-$0.44N/AN/AN/AN/A-11.34%-10.73%8/13/2025 (Estimated)SESNSesen Bio-$19.88M-$0.10N/AN/AN/AN/A6.70%5.41%N/ALatest ONCY, AVEO, ORMP, CBIO, and SESN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025ORMPOramed Pharmaceuticals-$0.03-$0.19-$0.16-$0.19N/A$2.00 million5/14/2025Q1 2025ONCYOncolytics Biotech-$0.09-$0.06+$0.03-$0.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVEOAVEO PharmaceuticalsN/AN/AN/AN/AN/ACBIOCrescent BiopharmaN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/AORMPOramed PharmaceuticalsN/AN/AN/AN/AN/ASESNSesen BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVEOAVEO Pharmaceuticals0.942.372.35CBIOCrescent BiopharmaN/A2.292.29ONCYOncolytics BiotechN/A3.203.20ORMPOramed PharmaceuticalsN/A23.9423.94SESNSesen BioN/A6.106.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVEOAVEO Pharmaceuticals49.95%CBIOCrescent Biopharma75.19%ONCYOncolytics Biotech6.82%ORMPOramed Pharmaceuticals12.73%SESNSesen Bio16.45%Insider OwnershipCompanyInsider OwnershipAVEOAVEO Pharmaceuticals3.29%CBIOCrescent Biopharma8.70%ONCYOncolytics Biotech0.10%ORMPOramed Pharmaceuticals13.70%SESNSesen Bio3.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVEOAVEO Pharmaceuticals11434.76 million33.62 millionOptionableCBIOCrescent Biopharma5019.55 million17.85 millionNo DataONCYOncolytics Biotech3094.28 million94.19 millionNot OptionableORMPOramed Pharmaceuticals1040.85 million35.25 millionOptionableSESNSesen Bio35203.49 million196.98 millionOptionableONCY, AVEO, ORMP, CBIO, and SESN HeadlinesRecent News About These CompaniesTrey MewesApril 9, 2024 | startribune.comSDevin Haney: biography, record, fights and moreDecember 9, 2023 | espn.comTyson Fury: Biography, record, fights and moreDecember 2, 2023 | espn.comWhy the Tucker Carlson Biography Sales Are So PatheticSeptember 13, 2023 | thedailybeast.comTSesen Bio (NASDAQ: SESN)August 4, 2023 | fool.comJames McTeigue Biography & MoviesMay 10, 2023 | tribute.caTAfter revisions, Philadelphia-based Carisma Therapeutics poised to close merger with Sesen BioMarch 6, 2023 | bizjournals.comSesen Bio wins shareholder approval for Carisma mergerMarch 2, 2023 | msn.comSesen Bio Stockholders Approve Merger with Carisma TherapeuticsMarch 2, 2023 | finance.yahoo.comSesen Bio Reports Fourth Quarter and Full-Year 2022 Financial ResultsFebruary 28, 2023 | finance.yahoo.comSHAREHOLDER ALERT: Weiss Law Reminds SESN, MLVF, VLON, and SHBI Shareholders About Its Ongoing InvestigationsFebruary 24, 2023 | benzinga.comLeading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote "FOR" All Proposals to Approve Pending Merger With CarismaFebruary 21, 2023 | finance.yahoo.comBML, One of Sesen Bio's Top Stockholders, Announces Support for Pending Merger with Carisma TherapeuticsFebruary 17, 2023 | stockhouse.comLeading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special MeetingFebruary 16, 2023 | businesswire.comSesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending MergerFebruary 16, 2023 | finance.yahoo.comSesen Bio reaches deal with investor group, paving way for Carisma mergerFebruary 15, 2023 | endpts.comELatest terms of Sesen Bio and Carisma merger appear to pass musterFebruary 15, 2023 | thepharmaletter.comT5 big dividend moves: Group 1 Automotive hikes by 20% | Pro RecapFebruary 15, 2023 | finance.yahoo.comBML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma TherapeuticsFebruary 15, 2023 | finance.yahoo.comSesen Bio, Carisma Therapeutics amend merger deal after reaching agreement with investor groupFebruary 14, 2023 | bizjournals.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeONCY, AVEO, ORMP, CBIO, and SESN Company DescriptionsAVEO Pharmaceuticals NASDAQ:AVEOAVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.Crescent Biopharma NASDAQ:CBIO$15.89 +0.34 (+2.19%) As of 07/3/2025 12:59 PM EasternCrescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.Oncolytics Biotech NASDAQ:ONCY$0.90 +0.11 (+14.41%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$0.90 +0.00 (+0.44%) As of 05:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.Oramed Pharmaceuticals NASDAQ:ORMP$2.18 +0.02 (+1.11%) Closing price 07/3/2025 01:10 PM EasternExtended Trading$2.16 -0.02 (-1.10%) As of 04:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.Sesen Bio NASDAQ:SESNSesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.